Global Parliamentarians Take the Stage at WHA78: A New Chapter in Health Governance The Seventy-eighth World Health Assembly (WHA78), held in Geneva in 2025, emerged as a landmark moment in the global health landscape, defined by sweeping decisions and a…
FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a significant regulatory milestone from the U.S. Food and Drug Administration…
argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases, presented encouraging new clinical data at the 2025 European Congress…
Bayer and Broad Institute Extend Landmark Collaboration to Advance Cardiovascular Genomics and Precision Medicine In a bold continuation of a decade-long scientific alliance, Bayer and the Broad Institute of MIT and Harvard have announced a five-year extension of their ongoing…
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the pivotal Phase 3 POETYK PsA-1 trial, reinforcing the potential of…
FDA Expands Approval of AbbVie’s MAVYRET® as First and Only 8-Week Treatment for Acute Hepatitis C in Adults and Children Aged 3 and Above AbbVie has received a significant regulatory boost for its hepatitis C treatment portfolio as the U.S.…
Ascendis Pharma Reports Promising Week 26 Results from COACH Trial: TransCon hGH Enhances TransCon CNP Benefits in Children with Achondroplasia Ascendis Pharma A/S, a global biopharmaceutical company focused on developing innovative therapies for rare diseases and endocrine disorders, has announced…
WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health Organization (WHO) convened the fourth meeting of the International Health…
Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the prestigious SLEEP 2025 conference, unveiling Phase 4 clinical results that…
Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for an expanded indication of its RNAi drug AMVUTTRA® (vutrisiran). The…
Merck’s Pimicotinib Accepted for Priority Review in China, Offering Hope for Patients with TGCT Merck, a prominent global science and technology company, announced a significant milestone in its oncology portfolio as the Center for Drug Evaluation (CDE) under China’s National…
FDA Approves Merck’s ENFLONSIA™ to Protect Infants from Severe RSV Illness Merck operating as MSD outside the United States and Canada, has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor).…